-
The private equity giant with a track record of taking firms public would add the IBD to its list of more than 850 investments for $73 billion worldwide.
February 25
-
The No. 1 IBD is pitching advisors on the merits of its offerings — but rivals have also added major teams from its ranks.
February 22
-
The IBD is one of three dozen firms the regulator has accused of failing to provide sales-charge waivers to eligible retirement plans and charities since 2015.
February 21
-
The new standalone firm’s first licensing agreement would bring MassMutual’s 9,000 reps on to the platform developed by the No. 4 IBD.
February 20
-
The CEO said his decision to resign followed a physician’s recommendation in connection with an undisclosed medical problem.
February 19
-
The No. 1 IBD’s efforts display opportunity amid the shortcomings of an industry still lacking measurable data from some of its largest firms.
February 19
-
The tax-focused IBD’s custodial and platform transition is taking longer than the company or its advisors expected.
February 14
-
It's the first regulatory ding for the influential advisor and entrepreneur in almost 15 years.
February 13
-
The No. 1 IBD plans to offer training and education and team up with reps on outreach to officials.
February 13
-
Clients have received a combined $3.7 million in settlements involving two barred former reps of the IBD set to be acquired by Atria Wealth Solutions.
February 12
